Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

german flag

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

- PMLiVE

AZ drug for opioid constipation clears phase III

Company hopes to file naloxegol in third quarter of 2013

UK flag

MRC funds UK research using 22 AstraZeneca compounds

Provides £7m for projects covering Alzheimer’s, cancer, lung disease and rare conditions

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links